Study of epcoritamab and ibrutinib for central nervous system lymphoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of lymphoma called diffuse large B-cell lymphoma that has been confirmed by a biopsy.
- You must be able to take care of most daily tasks yourself (ECOG score 0-2).
- Your blood counts (neutrophils, platelets, hemoglobin) must be within certain levels, and your liver and kidney function must be adequate.
- If you are able to have children, you must agree to use highly effective birth control during treatment and for a period after.
- You must not have active infections like HIV, hepatitis B or C, or uncontrolled COVID-19.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This trial tests a combination of three drugs (high-dose methotrexate, thiotepa, and zanubrutinib) for people who have just been diagnosed with primary central nervous system lymphoma (PCNSL). The goal is to see if this three-drug cocktail works better than standard treatments.
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.